Ticker Symbol: TOS/TSX
Shares Outstanding: 46 244 102
QUEBEC CITY, Oct. 23 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces the sale of a 125L Ozone Sterilizer to a Canadian hospital, which
was awarded following a tender.
This hospital's tender was designed to answer a need for another low
temperature sterilizer, as well as to comply with the Canadian regulations
that pursue the goal of reducing the emission of ethylene oxide, a toxic gas
often used in sterilization. For the purpose of the tender, the 125L Ozone
Sterilizer was thoroughly analysed and favourably compared to competition.
"Once again, ozone sterilization appears to be the preferred option for a
Canadian hospital that wishes to comply to Environment Canada regulations,
while enjoying the many benefits of a simple, efficacious and economical
method for sterilization", stated Jocelyn Vézina, CEO for TSO3 Inc.
As a reminder, Environment Canada has asked hospitals to reduce their
release of Ethylene Oxide into the environment by 99%. For more information,
please see the "Guidelines for the Reduction of Ethylene Oxide Releases from
Sterilization Applications" at the following address:
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 65 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, email@example.com; Source: TSO3